Last reviewed · How we verify
Endocrine therapy combined with trastuzumab
Endocrine therapy combined with trastuzumab is a Combination therapy: endocrine agent + HER2-targeted monoclonal antibody Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Hormone receptor-positive, HER2-positive metastatic or advanced breast cancer. Also known as: Tamoxifen, aromatase inhibitors, trastuzumab.
This combination therapy blocks estrogen receptor signaling while simultaneously inhibiting HER2-mediated growth pathways in hormone receptor-positive, HER2-positive breast cancer.
This combination therapy blocks estrogen receptor signaling while simultaneously inhibiting HER2-mediated growth pathways in hormone receptor-positive, HER2-positive breast cancer. Used for Hormone receptor-positive, HER2-positive metastatic or advanced breast cancer.
At a glance
| Generic name | Endocrine therapy combined with trastuzumab |
|---|---|
| Also known as | Tamoxifen, aromatase inhibitors, trastuzumab |
| Sponsor | Sun Yat-sen University |
| Drug class | Combination therapy: endocrine agent + HER2-targeted monoclonal antibody |
| Target | Estrogen receptor (ER) and HER2 (human epidermal growth factor receptor 2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Endocrine therapy (such as aromatase inhibitors, tamoxifen, or fulvestrant) suppresses estrogen-driven proliferation by blocking estrogen receptor activity or reducing estrogen production. Trastuzumab is a monoclonal antibody that targets HER2 and prevents HER2-mediated cell growth signaling. Together, they address two complementary oncogenic pathways in breast cancers that express both hormone receptors and HER2.
Approved indications
- Hormone receptor-positive, HER2-positive metastatic or advanced breast cancer
Common side effects
- Hot flashes
- Fatigue
- Nausea
- Cardiac dysfunction (from trastuzumab)
- Arthralgia/myalgia
Key clinical trials
- To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer (PHASE1)
- De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer (PHASE2)
- TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (PHASE2)
- A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer (PHASE3)
- Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery (PHASE2)
- Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa (PHASE2)
- A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (PHASE1)
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Endocrine therapy combined with trastuzumab CI brief — competitive landscape report
- Endocrine therapy combined with trastuzumab updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Endocrine therapy combined with trastuzumab
What is Endocrine therapy combined with trastuzumab?
How does Endocrine therapy combined with trastuzumab work?
What is Endocrine therapy combined with trastuzumab used for?
Who makes Endocrine therapy combined with trastuzumab?
Is Endocrine therapy combined with trastuzumab also known as anything else?
What drug class is Endocrine therapy combined with trastuzumab in?
What development phase is Endocrine therapy combined with trastuzumab in?
What are the side effects of Endocrine therapy combined with trastuzumab?
What does Endocrine therapy combined with trastuzumab target?
Related
- Drug class: All Combination therapy: endocrine agent + HER2-targeted monoclonal antibody drugs
- Target: All drugs targeting Estrogen receptor (ER) and HER2 (human epidermal growth factor receptor 2)
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Hormone receptor-positive, HER2-positive metastatic or advanced breast cancer
- Also known as: Tamoxifen, aromatase inhibitors, trastuzumab
- Compare: Endocrine therapy combined with trastuzumab vs similar drugs
- Pricing: Endocrine therapy combined with trastuzumab cost, discount & access